RATIONALE: Due to the episodic and chronic nature of bipolar disorder (BD), maintenance therapy represents a critical part of treatment; however, there is a paucity of studies comparing effectiveness of available long-term treatments. OBJECTIVE: The aim of this study is to determine and compare the efficacy of pharmacological treatments for maintenance treatment of BD by means of the number needed to treat (NNT). METHODS: The efficacy of drugs used for maintenance treatment of BD, as emerging from the results of randomized controlled trials, was assessed using the size effect measure of NNT. PubMed searches were conducted on English-language articles published until May 2010 using the search terms "bipolar disorder," "mania," "mixed episode," or "bipolar depression," cross-referenced with trial characteristic search phrases and generic names of medications. The search was supplemented by manually reviewing reference lists from identified publications. RESULTS: In 15 studies, aripiprazole, olanzapine, quetiapine, risperidone long-acting injection, lithium, lamotrigine, and divalproex proved effectiveness in terms of NNTs (≥ 10% advantage over placebo) for prevention of relapse into any mood episode. Quetiapine, lithium, risperidone long-acting injection, aripiprazole, and olanzapine are effective in manic recurrence prevention. Lamotrigine, quetiapine, and lithium present significant NNTs for prevention of depressive relapses. CONCLUSIONS: All of the pharmacological agents assessed were effective in the prevention of any kind of mood episode; however, different efficacy profiles were found for prevention of manic and/or depressive relapses. The comparison of NNT values of the available agents may represent a useful tool in clinical settings, in order to facilitate implementation of long-term pharmacological interventions in patients with BD.
RATIONALE: Due to the episodic and chronic nature of bipolar disorder (BD), maintenance therapy represents a critical part of treatment; however, there is a paucity of studies comparing effectiveness of available long-term treatments. OBJECTIVE: The aim of this study is to determine and compare the efficacy of pharmacological treatments for maintenance treatment of BD by means of the number needed to treat (NNT). METHODS: The efficacy of drugs used for maintenance treatment of BD, as emerging from the results of randomized controlled trials, was assessed using the size effect measure of NNT. PubMed searches were conducted on English-language articles published until May 2010 using the search terms "bipolar disorder," "mania," "mixed episode," or "bipolar depression," cross-referenced with trial characteristic search phrases and generic names of medications. The search was supplemented by manually reviewing reference lists from identified publications. RESULTS: In 15 studies, aripiprazole, olanzapine, quetiapine, risperidone long-acting injection, lithium, lamotrigine, and divalproex proved effectiveness in terms of NNTs (≥ 10% advantage over placebo) for prevention of relapse into any mood episode. Quetiapine, lithium, risperidone long-acting injection, aripiprazole, and olanzapine are effective in manic recurrence prevention. Lamotrigine, quetiapine, and lithium present significant NNTs for prevention of depressive relapses. CONCLUSIONS: All of the pharmacological agents assessed were effective in the prevention of any kind of mood episode; however, different efficacy profiles were found for prevention of manic and/or depressive relapses. The comparison of NNT values of the available agents may represent a useful tool in clinical settings, in order to facilitate implementation of long-term pharmacological interventions in patients with BD.
Authors: J R Calabrese; T Suppes; C L Bowden; G S Sachs; A C Swann; S L McElroy; V Kusumakar; J A Ascher; N L Earl; P L Greene; E T Monaghan Journal: J Clin Psychiatry Date: 2000-11 Impact factor: 4.384
Authors: C L Bowden; J R Calabrese; S L McElroy; L Gyulai; A Wassef; F Petty; H G Pope; J C Chou; P E Keck; L J Rhodes; A C Swann; R M Hirschfeld; P J Wozniak Journal: Arch Gen Psychiatry Date: 2000-05
Authors: Mauricio Tohen; Joseph R Calabrese; Gary S Sachs; Michael D Banov; Holland C Detke; Richard Risser; Robert W Baker; James C-Y Chou; Charles L Bowden Journal: Am J Psychiatry Date: 2006-02 Impact factor: 18.112
Authors: Eduard Vieta; Nuria Cruz; Javier García-Campayo; Rosario de Arce; Jose Manuel Crespo; Vicens Vallès; Josefina Pérez-Blanco; Ernesto Roca; Jose Manuel Olivares; Angel Moríñigo; Raul Fernández-Villamor; Merce Comes Journal: Int J Neuropsychopharmacol Date: 2008-03-17 Impact factor: 5.176
Authors: Paul E Keck; Joseph R Calabrese; Roger S McIntyre; Robert D McQuade; William H Carson; James M Eudicone; Berit X Carlson; Ronald N Marcus; Raymond Sanchez Journal: J Clin Psychiatry Date: 2007-10 Impact factor: 4.384
Authors: Guy M Goodwin; Charles L Bowden; Joseph R Calabrese; Heinz Grunze; Siegfried Kasper; Robin White; Paul Greene; Robert Leadbetter Journal: J Clin Psychiatry Date: 2004-03 Impact factor: 4.384
Authors: Konstantinos N Fountoulakis; Lakshmi Yatham; Heinz Grunze; Eduard Vieta; Allan Young; Pierre Blier; Siegfried Kasper; Hans Jurgen Moeller Journal: Int J Neuropsychopharmacol Date: 2017-02-01 Impact factor: 5.176
Authors: Julia Volkert; Kathrin C Zierhut; Miriam A Schiele; Martina Wenzel; Juliane Kopf; Sarah Kittel-Schneider; Andreas Reif Journal: BMC Psychiatry Date: 2014-11-22 Impact factor: 3.630
Authors: Leonardo Tondo; Martin Alda; Michael Bauer; Veerle Bergink; Paul Grof; Tomas Hajek; Ute Lewitka; Rasmus W Licht; Mirko Manchia; Bruno Müller-Oerlinghausen; René E Nielsen; Marylou Selo; Christian Simhandl; Ross J Baldessarini Journal: Int J Bipolar Disord Date: 2019-07-22